Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).

Taxane Chemotherapy ◽

Abstract P1-07-12: An exploratory correlative biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer

10.1158/1538-7445.sabcs16-p1-07-12 ◽

2017 ◽

Author(s):

PG Gavin ◽

PS Kim ◽

C Lipchick ◽

E Langley ◽

H Feng ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Neoadjuvant Therapy ◽

Phase Ii ◽

Locally Advanced ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Biomarker Analysis ◽

Abstract PD5-04: NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer

10.1158/1538-7445.sabcs15-pd5-04 ◽

2016 ◽

Cited By ~ 3

Author(s):

SA Jacobs ◽

A Robidoux ◽

JMP Garcia ◽

J Abraham ◽

N La Verde ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Neoadjuvant Therapy ◽

Phase Ii ◽

Locally Advanced ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Abstract OT-28-02: Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive / HER2-positive breast cancer - The TOUCH trial

10.1158/1538-7445.sabcs20-ot-28-02 ◽

2021 ◽

Author(s):

Laura Biganzoli ◽

Etienne Brain ◽

Luca Malorni ◽

Andrea Gombos ◽

Ursula Hasler-Strub ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Randomized Trial ◽

Postmenopausal Women ◽

Phase Ii ◽

Her2 Positive ◽

Estrogen Receptor Positive ◽

Faculty Opinions recommendation of Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.724195112.793501041 ◽

2014 ◽

Author(s):

Minesh Mehta ◽

Manmeet Ahluwalia

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Multicenter Phase ◽

Abstract PS13-14: A randomized, opened, phase II trial assessing the efficacy and safety of ATH-TH(doxorubicin/docetaxel/trastuzumab followed by docetaxel/trastuzumab) versus TCH(docetaxel/carboplatin/trastuzumab) as neoadjuvant treatment in HER2-positive breast cancer

10.1158/1538-7445.sabcs20-ps13-14 ◽

2021 ◽

Author(s):

Tao Wang ◽

Jin-Mei Zhou ◽

Xiao-Peng Hao ◽

Hui-Qaing Zhang ◽

Shao-Hua Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Neoadjuvant Treatment with Docetaxel Plus Lapatinib (L), Trastuzumab (T), or Both Followed By an Anthracycline Based Chemotherapy in Her2-Positive Breast Cancer: Results of the Randomised Phase Ii Eortc 10054 Study

Annals of Oncology ◽

10.1093/annonc/mdu327.1 ◽

2014 ◽

Vol 25 ◽

pp. iv85 ◽

Cited By ~ 1

Author(s):

H. Bonnefoi ◽

W. Jacot ◽

M. Saghatchian ◽

C. Moldovan ◽

L. Venat-Bouvet ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Neoadjuvant Treatment ◽

Her2 Positive ◽

All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study

Journal of the Egyptian National Cancer Institute ◽

10.1016/j.jnci.2014.08.001 ◽

2014 ◽

Vol 26 (4) ◽

pp. 187-194 ◽

Cited By ~ 9

Author(s):

Hanan Shawky ◽

Hesham Tawfik

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Abstract OT1-1-09: Opti-HER HEART: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER2-positive breast cancer.

10.1158/0008-5472.sabcs12-ot1-1-09 ◽

2012 ◽

Author(s):

J Gavilá ◽

A Llombart ◽

A Guerrero ◽

A Ruiz ◽

V Guillem

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Her2 Positive ◽

Abstract P1-08-36: Neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER). Analysis of biomarkers

10.1158/0008-5472.sabcs13-p1-08-36 ◽

2013 ◽

Author(s):

M Fernández ◽

N Martinez ◽

I Calvo ◽

E Garcia ◽

L Ugidos ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

10.1158/1538-7445.sabcs17-ot1-03-03 ◽

2018 ◽

Author(s):

A Musolino ◽

S Gori ◽

L Cavanna ◽

C Graiff ◽

A Frassoldati ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Mechanism Of Action ◽

Locally Advanced ◽

Her2 Positive ◽

Open Label ◽

Immune Mediated ◽